Clevudine

Drug Profile

Clevudine

Alternative Names: L-FMAU; Levovir; Revovir

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bukwang
  • Developer Bukwang Pharmaceutical; Eisai Co Ltd; Pharmasset
  • Class Antivirals; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 24 Jun 2015 No recent reports on development identified - Preregistration for Hepatitis B in China (PO)
  • 01 Sep 2014 Bukwang Pharmaceutical completes a phase III trial in Hepatitis B in South Korea (NCT00672867)
  • 01 Nov 2013 Eisai receives a non-approvable letter from the Chinese regulatory authority for clevudine for the treatment of chronic hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top